675 results on '"Stroes, Erik S.G."'
Search Results
2. LDLR variant classification for improved cardiovascular risk prediction in familial hypercholesterolemia
3. Plasma C-reactive protein is associated with a pro-inflammatory and adverse plaque phenotype
4. Oral Anaerobutyricum soehngenii augments glycemic control in type 2 diabetes
5. Development and Validation of a Quantitative Coronary CT Angiography Model for Diagnosis of Vessel-Specific Coronary Ischemia
6. Enhanced identification of familial hypercholesterolemia using central laboratory algorithms
7. Breaking the chains of lipoprotein lipase deficiency: A pediatric perspective on the efficacy and safety of Volanesorsen
8. AI-Guided Quantitative Plaque Staging Predicts Long-Term Cardiovascular Outcomes in Patients at Risk for Atherosclerotic CVD
9. Diacylglycerols and Lysophosphatidic Acid, Enriched on Lipoprotein(a), Contribute to Monocyte Inflammation
10. Tryptophan metabolites and incident cardiovascular disease: The EPIC-Norfolk prospective population study
11. Polygenic Background Modifies Risk of Coronary Artery Disease Among Individuals With Heterozygous Familial Hypercholesterolemia
12. Composition and distribution of lipoproteins after evolocumab in familial dysbetalipoproteinemia: A randomized controlled trial
13. Daring to dream: Targeting lipoprotein(a) as a causal and risk-enhancing factor
14. Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society
15. Volanesorsen and triglyceride levels in familial chylomicronemia syndrome: Long-term efficacy and safety data from patients in an open-label extension trial
16. Plasma Lipoprotein Lipase Is Associated with Risk of Future Major Adverse Cardiovascular Events in Patients Following Carotid Endarterectomy
17. Bempedoic acid lowers high-sensitivity C-reactive protein and low-density lipoprotein cholesterol: Analysis of pooled data from four phase 3 clinical trials
18. Major Facilitator Superfamily Domain Containing 5 Inhibition Reduces Lipoprotein(a) Uptake and Calcification in Valvular Heart Disease
19. Angiopoietin-like 3 inhibition and the liver: less is more?
20. Adherence to statin treatment in patients with familial hypercholesterolemia: A dynamic prediction model
21. Effect of evolocumab on fasting and post fat load lipids and lipoproteins in familial dysbetalipoproteinemia
22. Use of Lipoprotein(a) to improve diagnosis and management in clinical familial hypercholesterolemia
23. New Approaches for Targeting PCSK9: Small-Interfering Ribonucleic Acid and Genome Editing
24. Effect of PCSK9 Inhibition on the Plasma Proteome: A SPIRE SubStudy
25. Long-Term Safety and Efficacy of Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from the CLEAR Harmony Open-Label Extension Study)
26. Lipoprotein(a): An underestimated inflammatory mastermind
27. High lipoprotein(a) is associated with major adverse limb events after femoral artery endarterectomy
28. Reduced baroreflex sensitivity and increased splenic activity in patients with severe obstructive sleep apnea
29. Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study
30. Lipoprotein(a), venous thromboembolism and COVID-19: A pilot study
31. Assessment of practical applicability and clinical relevance of a commonly used LDL-C polygenic score in patients with severe hypercholesterolemia
32. Decreased LDL cholesterol exposure following ANGPTL3 inhibition reduces coronary plaque development in Homozygous Familial Hypercholesterolemia
33. Marked plaque regression in homozygous familial hypercholesterolemia
34. Consensus and guidelines on lipoprotein(a) – seeing the forest through the trees
35. Lipoprotein(a) and Long-Term Plaque Progression, Low-Density Plaque, and Pericoronary Inflammation.
36. Development and Validation of a Quantitative Coronary CT Angiography Model for Diagnosis of Vessel-Specific Coronary Ischemia.
37. Statin therapy reduces plasma angiopoietin-like 3 (ANGPTL3) concentrations in hypercholesterolemic patients via reduced liver X receptor (LXR) activation
38. Surmounting the endothelial barrier for delivery of drugs and imaging tracers
39. AHRR hypomethylation as an epigenetic marker of smoking history predicts risk of myocardial infarction in former smokers
40. No benefit of HDL mimetic CER-001 on carotid atherosclerosis in patients with genetically determined very low HDL levels
41. Electronic health records to facilitate continuous detection of familial hypercholesterolemia
42. Common gene variants in ASGR1 gene locus associate with reduced cardiovascular risk in absence of pleiotropic effects
43. The dedicated “Lp(a) clinic”: A concept whose time has arrived?
44. Therapeutic Antibody Against Phosphorylcholine Preserves Coronary Function and Attenuates Vascular 18F-FDG Uptake in Atherosclerotic Mice
45. AI-Guided Quantitative Plaque Staging Predicts Long-Term Cardiovascular Outcomes in Patients at Risk for Atherosclerotic CVD
46. Breaking the chains of lipoprotein lipase deficiency: A pediatric perspective on the efficacy and safety of Volanesorsen
47. Lipoprotein(a) and Long-Term Plaque Progression, Low-Density Plaque, and Pericoronary Inflammation
48. Diacylglycerols and Lysophosphatidic Acid, Enriched on Lipoprotein(a), Contribute to Monocyte Inflammation
49. Unexpected gaps in knowledge of familial hypercholesterolaemia among Dutch general practitioners
50. A 3-SNP gene risk score and a metabolic risk score both predict hypertriglyceridemia and cardiovascular disease risk
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.